Skip to main content

3 Percent of Youth Testing Positive for COVID-19 in ED Have Severe Outcomes

FRIDAY, Jan. 14, 2022 -- Approximately 3 percent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive youth tested in emergency departments experience severe outcomes within two weeks of their index visit, according to a study published online Jan. 11 in JAMA Network Open.

Anna L. Funk, Ph.D., from the University of Calgary in Alberta, Canada, and colleagues estimated the proportion of children with severe COVID-19 outcomes within 14 days of testing positive for SARS-CoV-2 in an emergency department (March 2020 to June 2021). The analysis included 3,222 youth seen in 41 emergency departments across 10 countries.

The researchers found that after 14 days of follow-up, 22.8 percent of children were hospitalized, 3.3 percent of whom had severe outcomes, and four children died (0.12 percent). Severe outcomes were associated with being aged 5 to 18 years (age 5 to <10 years versus <1 year: odds ratio [OR], 1.60; age 10 to <18 years versus <1 year: OR, 2.39) and having a self-reported chronic illness (OR, 2.34), a prior episode of pneumonia (OR, 3.15), and symptoms starting four to seven days prior to seeking emergency care (versus starting three or fewer days before seeking care: OR, 2.22). In a subgroup of 2,510 children discharged home from the emergency department who had complete follow-up, 2 percent were eventually hospitalized and 0.5 percent had severe outcomes.

"The findings of this study suggest that risk factors such as age, underlying chronic illness, and symptom duration may be useful for clinicians to consider when evaluating pediatric patients with SARS-CoV-2 infection," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

© 2022 HealthDay. All rights reserved.

Read this next

Racial, Ethnic Disparities Seen in mAb Treatment for COVID-19

WEDNESDAY, Jan. 19, 2022 -- There are racial and ethnic disparities in receipt of monoclonal antibody (mAb) treatment among patients with COVID-19, according to research published...

BNT162b2 Vaccine Effective Against Severe COVID-19 in Adolescents

WEDNESDAY, Jan. 19, 2022 -- Two doses of the BNT162b2 vaccine are highly effective against COVID-19-related hospitalization and critical disease in adolescents aged 12 to 18...

AI Model May Predict COVID-19 Outcomes for Critically Ill

WEDNESDAY, Jan. 19, 2022 – Using proteomics data, a machine learning model may predict survival in critically ill COVID-19 patients, according to a study published online...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.